GlycoMimetics Awarded NIH Grant to Study Drug Candidate in Diabetes
News Aug 18, 2009
GlycoMimetics, Inc. has announced it has been awarded a grant from The National Heart, Lung, and Blood Institute (NHLBI) of The National Institutes of Health (NIH) to evaluate its E-selectin small molecule antagonists in animal models of vascular complications of diabetes.
The grant is based upon substantial data in the scientific literature suggesting an important role for E-selectin in the chronic inflammation associated with diabetes. The company has developed a family of potent small molecule E-selectin antagonists which it is currently optimizing for oral availability.
“We are excited about the potential for our E-selectin antagonists to treat or prevent vascular complications of diabetes, and we believe GlycoMimetics’ family of small molecule therapeutics could represent a breakthrough in this field,” said John Magnani, Ph.D., GlycoMimetics’ Vice President and Chief Scientific Officer. “It is gratifying to have this important research recognized by the NIH.”
Elevated levels of E-selectin have been shown to correlate with increased risk of complications related to poor microvascular blood flow, such as diabetic retinopathy and nephropathy. GlycoMimetics has discovered a class of potent E-selectin inhibitors, one of which, in earlier tests, was shown to improve blood flow by inhibiting leukocyte rolling and adhesion in diabetic mice.
The company believes that E-selectin antagonists could also be beneficial in treating certain inflammatory skin conditions where E-selectin plays an important role.